Universal Vision Biotechnology Co Ltd Asset Resilience Ratio
Universal Vision Biotechnology Co Ltd asset resilience ratio. Universal Vision Biotechnology Co Ltd (3218) has an Asset Resilience Ratio of 21.73% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 3218 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Universal Vision Biotechnology Co Ltd (2007–2025)
Asset resilience ratio of Universal Vision Biotechnology Co Ltd from 2007 to 2025. This chart shows how Universal Vision Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. See 3218 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Universal Vision Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Universal Vision Biotechnology Co Ltd asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.32 Billion | 21.73% |
| Total Liquid Assets | NT$1.32 Billion | 21.73% |
Asset Resilience Insights
- Good Liquidity Position: Universal Vision Biotechnology Co Ltd maintains a healthy 21.73% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Universal Vision Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Universal Vision Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ramsay Health Care Ltd
AU:RHC |
Medical Care Facilities | 3.49% |
|
Encompass Health Corp
NYSE:EHC |
Medical Care Facilities | 0.51% |
|
Sienna Senior Living Inc
TO:SIA |
Medical Care Facilities | 0.09% |
|
Regis Healthcare Ltd
AU:REG |
Medical Care Facilities | 2.29% |
|
Pacific Smiles Group Ltd
AU:PSQ |
Medical Care Facilities | 10.35% |
|
CareRx Corp
TO:CRRX |
Medical Care Facilities | 5.50% |
|
Oceania Healthcare Ltd
AU:OCA |
Medical Care Facilities | 0.01% |
|
Rede D'Or São Luiz S.A.
SA:RDOR3 |
Medical Care Facilities | 39.18% |
Universal Vision Biotechnology Co Ltd Asset Resilience Ratio by Year (2007–2025)
Universal Vision Biotechnology Co Ltd asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Universal Vision Biotechnology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 21.73% | NT$1.32 Billion ≈ $41.71 Million |
NT$6.09 Billion ≈ $191.97 Million |
-2.75pp |
| 2024-12-31 | 24.48% | NT$1.41 Billion ≈ $44.44 Million |
NT$5.76 Billion ≈ $181.56 Million |
+13.21pp |
| 2023-12-31 | 11.27% | NT$578.36 Million ≈ $18.22 Million |
NT$5.13 Billion ≈ $161.64 Million |
-1.52pp |
| 2022-12-31 | 12.80% | NT$576.62 Million ≈ $18.17 Million |
NT$4.51 Billion ≈ $141.96 Million |
-0.69pp |
| 2021-12-31 | 13.49% | NT$505.81 Million ≈ $15.94 Million |
NT$3.75 Billion ≈ $118.13 Million |
-1.08pp |
| 2020-12-31 | 14.57% | NT$461.75 Million ≈ $14.55 Million |
NT$3.17 Billion ≈ $99.85 Million |
+1.77pp |
| 2019-12-31 | 12.80% | NT$338.97 Million ≈ $10.68 Million |
NT$2.65 Billion ≈ $83.40 Million |
-4.29pp |
| 2018-12-31 | 17.09% | NT$358.41 Million ≈ $11.29 Million |
NT$2.10 Billion ≈ $66.06 Million |
+7.87pp |
| 2017-12-31 | 9.22% | NT$184.89 Million ≈ $5.83 Million |
NT$2.00 Billion ≈ $63.15 Million |
-4.85pp |
| 2016-12-31 | 14.07% | NT$245.21 Million ≈ $7.73 Million |
NT$1.74 Billion ≈ $54.91 Million |
+8.04pp |
| 2015-12-31 | 6.03% | NT$113.99 Million ≈ $3.59 Million |
NT$1.89 Billion ≈ $59.54 Million |
-17.19pp |
| 2014-12-31 | 23.22% | NT$418.63 Million ≈ $13.19 Million |
NT$1.80 Billion ≈ $56.79 Million |
-1.52pp |
| 2013-12-31 | 24.75% | NT$337.88 Million ≈ $10.65 Million |
NT$1.37 Billion ≈ $43.02 Million |
+24.03pp |
| 2012-12-31 | 0.72% | NT$9.03 Million ≈ $284.53K |
NT$1.26 Billion ≈ $39.59 Million |
-1.31pp |
| 2011-12-31 | 2.03% | NT$28.10 Million ≈ $885.34K |
NT$1.38 Billion ≈ $43.59 Million |
+1.06pp |
| 2009-12-31 | 0.98% | NT$10.91 Million ≈ $343.60K |
NT$1.12 Billion ≈ $35.22 Million |
-0.04pp |
| 2008-12-31 | 1.01% | NT$11.03 Million ≈ $347.54K |
NT$1.09 Billion ≈ $34.34 Million |
-13.41pp |
| 2007-12-31 | 14.42% | NT$101.63 Million ≈ $3.20 Million |
NT$704.59 Million ≈ $22.20 Million |
-- |
About Universal Vision Biotechnology Co Ltd
Universal Vision Biotechnology Co., Ltd. operates a chain of eye care clinics in Taiwan and China. The company offers optical instruments, eyeglasses, contact lenses, and eyeglass accessories. It is also involved in eyeglasses optometry and dispensing services and leasing of medical devices. In addition, the company offers hospital management, optometric, and technical consultancy analysis, as we… Read more